Target intelligence / Profile preview

Intestinal mucosa and immune system (GALT)

Target
GALT
Molecular classification
Other
01

Overview

The intestinal mucosa and immune system, primarily organized as the gut-associated lymphoid tissue (GALT), constitute the body's largest immunological organ and a critical interface with the external environment. This system functions as a selective barrier that permits nutrient absorption while providing a robust defense against pathogens and maintaining tolerance to commensal microbiota and dietary antigens (Mowat & Agace, 2014, Nature Reviews Immunology). It consists of specialized epithelial cells, a protective mucus layer, and a diverse population of immune cells, including intraepithelial lymphocytes and plasma cells secreting IgA (Vancamelbeke & Vermeire, 2017, Therapeutic Advances in Gastroenterology). Dysregulation of the intestinal immune response or a breakdown in mucosal barrier integrity is a hallmark of chronic inflammatory conditions such as Crohn's disease and ulcerative colitis (Okumura & Takeda, 2017, International Immunology). Therapeutic strategies often involve modulating specific molecular pathways within this system, such as blocking tumor necrosis factor (TNF) or inhibiting the migration of lymphocytes to the gut via integrin antagonism (Danese et al., 2015, Gut).

Other names
Gut-associated lymphoid tissueMucosal immune systemIntestinal barrierIntestinal immune system
02

Mechanism of action

Drugs targeting this system typically act by inhibiting pro-inflammatory cytokines, blocking leukocyte trafficking to the gut, or providing local anti-inflammatory effects to restore mucosal barrier function.

03

Biological functions

Immune responseBarrier functionHomeostasisNutrient absorption
04

Disease associations

Inflammatory bowel diseaseCrohn's diseaseUlcerative colitisCeliac diseaseInfection
05

Safety considerations

Opportunistic infectionsInfusion reactionsIncreased risk of lymphomaLoss of response over time
06

Interacting drugs

Vedolizumab

4 more in the full profile.

07

Biomarkers

Fecal calprotectinC-reactive protein (CRP)Anti-Saccharomyces cerevisiae antibodies (ASCA)

Beyond the preview

Go deeper on Intestinal mucosa and immune system (GALT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal mucosa and immune system (GALT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call